Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I (Q24185933)

scientific article

Language	Label	Description	Also known as
English	Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I	scientific article

Statements

instance of

scholarly article

0 references

title

Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I (English)

0 references

main subject

enzyme replacement therapy

0 references

mucopolysaccharidosis I

1 reference

1 reference

3

Tracey Remmington

0 references

author name string

Elisabeth Jameson

series ordinal

1

0 references

Simon Jones

series ordinal

2

0 references

publication date

1 April 2016

0 references

published in

Cochrane Database of Systematic Reviews

0 references

cites work

Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

Enzyme-replacement therapy in mucopolysaccharidosis I.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

Standardization of Spirometry, 1994 Update. American Thoracic Society

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

Prevalence of lysosomal storage disorders

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

Mucopolysaccharidosis I: management and treatment guidelines

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

21 January 2018

Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD009354.PUB4

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD009354.PUB4

0 references

PubMed ID

27033167

0 references

Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I (Q24185933)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I (Q24185933)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search